IRRAS AB publishes Interim Report for the period January to June 2022
Continued progress during Q2 2022 ” The second quarter of 2022 provided the latest data point to confirm IRRAS’ progress toward becoming a leader in neurocritical care. Q2 represented the 8th consecutive quarter of revenue growth for our company, and our revenue of MSEK 9.7 (5.1) represents 13% growth over Q1 2022 and 90% growth from the same period last year.” ” Between normalized commercial activity, the initiation of the DIVES trial, and the stabilization of the company’s financial future, critical progress has been made, and, now, our focus can shift to taking the important next